Yang T J, Wei H L, Liu G T
Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, China.
Zhongguo Yao Li Xue Bao. 1997 Mar;18(2):185-8.
To evaluate anti-hepatitis drugs.
Mice were injected i.v. with viable BCG 5 x 10(7) (live) bacilli/mouse, after 10 d, i.v. lipopolysaccharides (LPS) 5-10 micrograms/mouse. Serum aminotransferase levels and liver tissue were examined 10 h after i.v. LPS. Sixteen drugs were evaluated in this model.
The level of AlaAT and AspAT were increased markedly. Submassive necrosis and infiltrations of granulocytes and lymphocytes were seen, which were not recovered till 14 d after i.v. LPS. Administration of interferon alpha-2a, Ara-AMP, hepatocyte growth factor, biphenyl dimethyl dicarboxylate, bicyclol, prednisolone, and cyclophosphamide for 10 d prior to i.v. LPS suppressed the elevation of serum AlaAT and AspAT.
The model of immunological liver injury reproduced by i.v. BCG + LPS in mice may be used for evaluating anti-hepatitis drugs.
评估抗肝炎药物。
给小鼠静脉注射5×10⁷活卡介苗(活菌)/只,10天后,静脉注射脂多糖(LPS)5 - 10微克/只。静脉注射LPS 10小时后检测血清转氨酶水平和肝组织。在该模型中评估了16种药物。
丙氨酸氨基转移酶(AlaAT)和天冬氨酸氨基转移酶(AspAT)水平显著升高。可见亚大块坏死以及粒细胞和淋巴细胞浸润,静脉注射LPS后14天仍未恢复。在静脉注射LPS前10天给予α-2a干扰素、阿糖腺苷单磷酸、肝细胞生长因子、联苯双酯、双环醇、泼尼松龙和环磷酰胺可抑制血清AlaAT和AspAT的升高。
静脉注射卡介苗+脂多糖在小鼠中复制的免疫性肝损伤模型可用于评估抗肝炎药物。